Effective this month, the U.S. Food and Drug Administration (FDA) has reclassified antigen-based, rapid influenza virus antigen detection test systems (RIDTs) used directly on clinical specimens from Class I to Class II devices. Further, the FDA is introducing special controls aimed at improving the overall quality of flu testing and reducing the number of misdiagnosed…

This content is for Paid Members only.
Login Register